Cargando…
Clinical Pharmacology of Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) are biopharmaceutical products where a monoclonal antibody is linked to a biologically active drug (a small molecule) forming a conjugate. Since the approval of first ADC (Gemtuzumab ozogamicin (trade name: Mylotarg)) for the treatment of CD33-positive acute myelogeno...
Autor principal: | Mahmood, Iftekhar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161445/ https://www.ncbi.nlm.nih.gov/pubmed/34063812 http://dx.doi.org/10.3390/antib10020020 |
Ejemplares similares
-
Effect of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Antibody–Drug Conjugates (ADCs)
por: Mahmood, Iftekhar
Publicado: (2021) -
Interspecies Scaling of Antibody–Drug Conjugates (ADC) for the Prediction of Human Clearance
por: Mahmood, Iftekhar
Publicado: (2021) -
Factors Affecting the Pharmacology of Antibody–Drug Conjugates
por: Lucas, Andrew T., et al.
Publicado: (2018) -
A Simple Method for the Prediction of Human Concentration–Time Profiles and Pharmacokinetics of Antibody–Drug Conjugates (ADC) from Rats or Monkeys
por: Mahmood, Iftekhar
Publicado: (2022) -
Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
por: Liu, Stephanie N., et al.
Publicado: (2021)